Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Incyte Corp (INCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,417,176
  • Shares Outstanding, K 212,580
  • Annual Sales, $ 1,536 M
  • Annual Income, $ -313,140 K
  • 36-Month Beta 1.14
  • Price/Sales 9.27
  • Price/Cash Flow 77.08
  • Price/Book 8.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.19
  • Number of Estimates 2
  • High Estimate 0.21
  • Low Estimate 0.16
  • Prior Year 0.17
  • Growth Rate Est. (year over year) +11.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
65.47 +2.66%
on 09/12/18
74.81 -10.16%
on 09/05/18
-1.59 (-2.31%)
since 08/17/18
3-Month
61.45 +9.37%
on 08/06/18
75.15 -10.57%
on 06/21/18
-5.77 (-7.91%)
since 06/19/18
52-Week
60.22 +11.60%
on 05/03/18
118.61 -43.34%
on 09/20/17
-49.88 (-42.60%)
since 09/19/17

Most Recent Stories

More News
Agenus Receives Milestone Payment of $5 Million from Incyte

Agenus (AGEN) receives a milestone payment of $5 million from Incyte on the initiation of a phase I study of INCAGN2385.

AGEN : 2.00 (+4.71%)
MRK : 70.11 (-0.44%)
INCY : 67.25 (-0.84%)
GILD : 73.87 (+0.27%)
Merck Gets Priority Review for Yet Another Keytruda sBLA

Merck's (MRK) sBLA to include overall survival data from a key lung cancer study on Keytruda's label gets FDA's priority review. If approved, it will expand the eligible patient population.

MRK : 70.11 (-0.44%)
INCY : 67.25 (-0.84%)
AMGN : 203.17 (+0.41%)
GSK : 39.56 (-0.18%)
In Honor of MPN Awareness Day and Blood Cancer Awareness Month, Incyte Debuts Documentary Spotlighting Myeloproliferative Neoplasms (MPNs)

--MPN community encouraged to access new resources and participate in awareness initiatives in support of MPN Awareness Day

INCY : 67.25 (-0.84%)
Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis

--Results presented at EADV support planned initiation of global, pivotal Phase 3 program

INCY : 67.25 (-0.84%)
Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars

Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.

PRQR : 20.25 (+0.25%)
INCY : 67.25 (-0.84%)
GILD : 73.87 (+0.27%)
REGN : 382.78 (-1.43%)
SNY : 43.85 (-0.25%)
Incyte, Foundation Medicine Partner for Companion Diagnostics

Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.

LLY : 105.95 (-0.87%)
INCY : 67.25 (-0.84%)
NVS : 84.74 (-0.34%)
GILD : 73.87 (+0.27%)
Incyte Corp Set to Possibly Rebound After Yesterday's Selloff of 1.17%

Incyte Corp (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $66.35 to a high of $69.14. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $67.78...

INCY : 67.25 (-0.84%)
Merck's Keytruda Combo Gets Nod for Lung Cancer in Europe

Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting.

MRK : 70.11 (-0.44%)
LLY : 105.95 (-0.87%)
INCY : 67.25 (-0.84%)
AMGN : 203.17 (+0.41%)
Incyte and Foundation Medicine Announce Agreement to Develop Companion Diagnostic for Pemigatinib (INCB54828), a Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma

Incyte Corporation (NASDAQ:INCY) and Foundation Medicine, Inc., today announced that the companies have entered into an agreement for the development, regulatory support and commercialization...

FMI : 136.95 (-0.04%)
INCY : 67.25 (-0.84%)
Incyte Corp Set to Possibly Rebound After Yesterday's Selloff of 3.66%

Incyte Corp (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $69.05 to a high of $71.70. Yesterday, the shares fell 3.7%, which took the trading range below the 3-day low of $71.44...

INCY : 67.25 (-0.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade INCY with:

Business Summary

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis...

See More

Key Turning Points

2nd Resistance Point 68.85
1st Resistance Point 68.34
Last Price 67.25
1st Support Level 66.95
2nd Support Level 66.07

See More

52-Week High 118.61
Fibonacci 61.8% 96.31
Fibonacci 50% 89.42
Fibonacci 38.2% 82.53
Last Price 67.25
52-Week Low 60.22

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar